Latest Period
Q4 2025
CUSIP: 75915K309
Latest Period
Q4 2025
Institutions Reporting
0
Shares (Excl. Options)
0
Price
$8.20
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
Latest holder context comes from 0 institutions filings for Q4 2025.
What is CUSIP 75915K309?
CUSIP 75915K309 identifies RGLS - Regulus Therapeutics Inc. - Common Stock, par value $0.001 per share in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Use the next link that matches the question you still need to answer about this security.
Open recent reporting periods for CUSIP 75915K309:
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Vivo Opportunity Fund Holdings, L.P. | 3.9% | $9,086,956 | 2,696,426 | Vivo Opportunity Fund Holdings, L.P. | 31 Mar 2025 | |||
| Point72 Asset Management, L.P. | 0.3% | -93% | $1,977,487 | -$30,197,722 | 241,157 | -94% | Point72 Asset Management, L.P. | 30 Jun 2025 |
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 0 | $0 | -$132,628 | $8.20 | 0 |
| 2025 Q3 | $8.20 | 0 | |||
| 2025 Q2 | 0 | $0 | -$105,304,835 | $8.16 | 0 |
| 2025 Q1 | 53,596,381 | $105,311,940 | +$3,105,761 | $1.75 | 74 |
| 2024 Q4 | 53,508,570 | $84,543,374 | -$5,126,517 | $1.58 | 68 |
| 2024 Q3 | 56,729,933 | $89,079,771 | +$3,280,059 | $1.57 | 69 |
| 2024 Q2 | 54,841,321 | $97,892,529 | +$13,518,084 | $1.78 | 60 |
| 2024 Q1 | 45,620,114 | $128,657,473 | +$103,077,800 | $2.88 | 42 |
| 2023 Q4 | 9,168,367 | $11,735,268 | +$40,056 | $1.28 | 23 |
| 2023 Q3 | 8,956,428 | $12,343,312 | +$1,002,811 | $1.37 | 22 |
| 2023 Q2 | 8,228,751 | $12,096,772 | +$2,407,893 | $1.47 | 21 |
| 2023 Q1 | 6,598,665 | $5,593,075 | -$77,466 | $0.85 | 22 |
| 2022 Q4 | 6,670,905 | $9,138,408 | -$4,945 | $1.37 | 21 |
| 2022 Q3 | 6,668,921 | $11,336,000 | +$3,422,009 | $1.70 | 19 |
| 2022 Q2 | 4,622,322 | $9,565,000 | +$9,565,000 | $2.06 | 22 |